Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Tauzin’s First Steps: Play Up Patient Assistance, Tone Down Annual Meeting

Executive Summary

The Pharmaceutical Research & Manufacturers of America will hold its first annual meeting of the Tauzin era in Washington, D.C

You may also be interested in...



PhRMA CEO Tauzin Takes Over Jan. 3: PR Focus Begins At The Top

PhRMA's new management team under CEO Billy Tauzin will place a high priority on communications and partnerships with other stakeholders in healthcare policy debates

Medicare Rx Sponsors Must Notify CMS Of Part D Intentions In February

Potential Medicare Rx plan sponsors will need to tell the Centers for Medicare & Medicaid Services how they intend to participate in the Part D benefit by early February

PhRMA Agenda For 2005 Includes Medicare Start-Up, Liability Reform

The Pharmaceutical Research & Manufacturers of America will be supporting medical malpractice reform measures at the state level as part of its agenda for 2005

Related Content

Latest Headlines
See All
UsernamePublicRestriction

Register

PS045143

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel